Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 29Observational 6Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Large Cell 1Carcinoma 1Adenocarcinoma 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × brigatinib × Clear all
NCT02784158 2018-02-06

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Takeda

No longer available
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡